Harmonizome 3.0

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:H23 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:G04 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:K02 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:K08 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:K13 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:O06 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:G14 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:H07 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:D05 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:D11 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:G16 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:H24 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:N04 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:K09 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:C24 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:K01 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:K07 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:J06 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:G15 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:O19 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:P03 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:M13 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:A07 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:A08 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:A09 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:B13 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:D19 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:H08 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:K10 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:K11 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:K12 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:L19 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:O07 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:P07 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:G07 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:L03 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:C22 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:C23 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:O04 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:O03 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:O09 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:B19 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:C01 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:C02 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:C03 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:C04 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:E13 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:G08 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:G17 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:L20 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:L21 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:O08 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:O10 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:O11 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:O12 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:P01 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:P02 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:P04 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:P05 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:P08 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:P09 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:P10 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:N19 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:I22 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:O01 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:A06 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:A10 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:A12 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:A17 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:A19 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:A20 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:A21 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:A23 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:B03 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:B04 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:B06 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:B09 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:B10 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:B12 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:B17 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:B18 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:B20 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:C06 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:C12 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:C17 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:C19 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:C20 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:D08 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:D09 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:D13 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:D16 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:D17 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:D18 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:D22 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:D24 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:E01 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:E04 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:E06 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:E08 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:E10 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:E11 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:E15 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:E16 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:E19 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:E21 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:E24 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:F07 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:F12 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:F13 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:F17 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:F18 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:F20 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:G03 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:G09 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:G12 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:G18 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:G19 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:G20 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:G22 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:H01 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:H04 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:H05 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:H06 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:H09 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:H10 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:H11 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:H19 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:H20 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:H22 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:I02 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:I05 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:I10 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:I12 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:I13 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:I17 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:I18 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:I20 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:I21 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:J01 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:J08 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:J09 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:J14 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:J17 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:J18 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:J21 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:J24 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:K04 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:K05 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:K14 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:K15 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:K16 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:K17 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:K19 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:K20 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:K21 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:K22 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:K24 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:L06 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:L09 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:L10 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:L12 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:L14 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:L15 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:L22 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:M05 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:M07 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:M09 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:M12 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:M17 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:M19 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:M24 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:N01 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:N06 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:N07 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:N08 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:N17 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:N21 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:O05 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:O15 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:O21 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:O23 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:O24 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:P13 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:P19 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:O02 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:D01 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:N03 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:A04 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:C21 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:H17 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:A15 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:G11 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:H12 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:H14 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:I03 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:I07 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:L17 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:O14 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:H15 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:A03 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:A14 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:A22 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:C08 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:C14 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:C15 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:C16 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:D04 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:D07 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:D20 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:E18 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:F05 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:F09 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:F19 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:F21 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:G02 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:G05 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:G10 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:G23 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:G24 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:H02 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:I09 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:I16 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:J02 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:J05 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:J20 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:J23 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:L07 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:M10 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:M21 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:M22 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:M23 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:N09 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:N11 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:N14 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:P15 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:O20 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:B23 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:F16 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:J11 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:H21 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:N22 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:E14 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:E20 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:J10 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:J12 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:M15 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:N12 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:N24 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:M20 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:L13 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:B11 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:C13 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:D06 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:D02 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:A13 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:A24 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:B07 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:B22 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:C09 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:C18 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:D10 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:D12 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:E05 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:E07 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:E12 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:F15 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:F22 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:I08 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:J15 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:J16 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:K03 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:L05 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:M11 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:N05 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:N20 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:O13 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:O16 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:P16 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:P18 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:A16 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:B05 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:L02 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:P12 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:I15 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:P21 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:E23 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:A11 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:J03 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:L23 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:M03 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:P14 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:A05 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:E03 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:G01 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:I23 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:J19 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:M18 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:N18 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:O17 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:P17 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:P22 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:K23 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:D21 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:C11 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:F24 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:H13 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:I11 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:I14 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:J22 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:K06 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:L24 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:M04 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:N16 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:M01 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:A18 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:B15 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:B16 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:E22 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:F08 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:F11 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:F23 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:L11 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:M08 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:N15 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:P24 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:I19 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:D03 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:H03 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:E02 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:F06 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:N23 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:N10 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:P20 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:B14 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:F03 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:F04 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:H18 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:I01 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:J07 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:K18 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:M14 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:P23 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:C10 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:E09 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:L16 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:M06 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:B21 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:L08 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:E17 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:D14 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:H16 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:L18 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:M16 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:N13 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:J04 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:C07 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:F10 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:L04 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:F02 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:C05 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:G21 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:J13 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:N02 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:P06 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:M02 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:I04 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:O22 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:P11 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:D23 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:F14 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:O18 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:F01 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:I24 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:I06 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:B08 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:L01 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:B24 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:D15 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:G06 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From BioGPS Cell Line Gene Expression Profiles

genes with high or low expression in NCI H23 relative to other cell lines from the BioGPS Cell Line Gene Expression Profiles dataset.

From COSMIC Cell Line Gene CNV Profiles

genes with high or low copy number in NCI-H23 relative to other cell lines from the COSMIC Cell Line Gene CNV Profiles dataset.

From COSMIC Cell Line Gene Mutation Profiles

genes mutated in the NCI-H23 cell line from the COSMIC Cell Line Gene Mutation Profiles dataset.

From GDSC Cell Line Gene Expression Profiles

genes with high or low expression in NCI-H23 relative to other cell lines from the GDSC Cell Line Gene Expression Profiles dataset.

From Klijn et al., Nat. Biotechnol., 2015 Cell Line Gene CNV Profiles

genes with high or low copy number in NCI-H23 relative to other cell lines from the Klijn et al., Nat. Biotechnol., 2015 Cell Line Gene CNV Profiles dataset.

From Klijn et al., Nat. Biotechnol., 2015 Cell Line Gene Expression Profiles

genes with high or low expression in NCI-H23 relative to other cell lines from the Klijn et al., Nat. Biotechnol., 2015 Cell Line Gene Expression Profiles dataset.

From Klijn et al., Nat. Biotechnol., 2015 Cell Line Gene Mutation Profiles

genes mutated in the NCI-H23 cell line from the Klijn et al., Nat. Biotechnol., 2015 Cell Line Gene Mutation Profiles dataset.

From TISSUES Text-mining Tissue Protein Expression Evidence Scores

proteins co-occuring with the tissue nci-h23 cell in abstracts of biomedical publications from the TISSUES Text-mining Tissue Protein Expression Evidence Scores dataset.

From Sanger Dependency Map Cancer Cell Line Proteomics

proteins associated with the cell line NCI-H23 from the Sanger Dependency Map Cancer Cell Line Proteomics dataset.

From TISSUES Text-mining Tissue Protein Expression Evidence Scores 2025

proteins co-occuring with the tissue NCI-H23 cell in abstracts of biomedical publications from the TISSUES Text-mining Tissue Protein Expression Evidence Scores 2025 dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Bortezomib_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Ritonavir_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Neratinib (maleate)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Orlistat_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the DTP3_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Bexarotene_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Verteporfin_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Bendamustine_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Regorafenib_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Almonertinib (mesylate)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the ULK-101_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Cysteamine (hydrochloride)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pentamidine (isethionate)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the AZD-7648_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the vincristine_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Ropivacaine (hydrochloride monohydrate)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Furosemide_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Isocorydine_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the DT-061_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Gemcitabine_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Selinexor _NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the PF-06260933_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Fingolimod (hydrochloride)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Talc_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Econazole_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Dorzolamide (hydrochloride)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Levobupivacaine (hydrochloride)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Carbamazepine_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the L-Eflornithine (monohydrochloride)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Decitabine_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Triamcinolone_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the (S)-Crizotinib_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Tubulin inhibitor 6_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Dexmedetomidine_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Hydroxyfasudil_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Lonafarnib_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Rimonabant_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Ciclopirox_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Sapanisertib_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Allantoin_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the AZD2858_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the PH-797804_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Delamanid_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Gallic acid_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Raltitrexed_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Cilostazol_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the AZD-8055_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Belzutifan_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Drospirenone_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the NG25_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Tranilast_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Artesunate_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Anethole trithione_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Ferulic acid_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Riluzole hydrochloride_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Mifepristone_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Brivudine_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Ivabradine (hydrochloride)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Budesonide_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Oleic acid_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Fedratinib (hydrochloride hydrate)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Elagolix sodium_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Dexamethasone_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the AT7519_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Oxaliplatin_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Belumosudil (mesylate)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the ETC-206_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the AZD1390_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the CP21R7_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Temuterkib_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Clonidine (hydrochloride)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Diammonium Glycyrrhizinate_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Proglumide_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Bergenin_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the 18β-Glycyrrhetinic acid_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Flutamide_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Megestrol_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Anastrozole_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Cepharanthine_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Mebendazole_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pentagastrin_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Docetaxel_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Norepinephrine (hydrochloride)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Medroxyprogesterone acetate_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pyridoxine_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the ERK5-IN-2_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Phenytoin (sodium)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Peretinoin_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Omeprazole (sodium)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the IQ 1_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Sodium Salicylate_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Berbamine (dihydrochloride)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Daptomycin_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Atazanavir (sulfate)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Adenosine_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the (R)-Verapamil (hydrochloride)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Ixazomib_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Olanzapine_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Roxadustat_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Citalopram (hydrobromide)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Osimertinib (mesylate)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Digitoxin_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the NVP-BHG712_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the 4EGI-1_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Brimonidine_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Abiraterone acetate_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Entrectinib_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Diphenhydramine_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pimozide_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Bisoprolol (hemifumarate)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Adenine_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Vismodegib_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Arbutin_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Meloxicam_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Voriconazole_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Tetracycline (hydrochloride)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Esmolol (hydrochloride)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Ribociclib_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Relugolix_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Darolutamide_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Temsirolimus_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Minodronic acid_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Fulvestrant_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Lopinavir_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Radotinib_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Piroxicam_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Rapamycin_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Vortioxetine_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Idoxuridine_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Baicalin_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Abemaciclib_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Gefitinib_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Berbamine_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Dapagliflozin_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the TAK-733_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the LB-100_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the crizotinib_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Dabrafenib_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Lucanthone_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Fusidic acid_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Cyclosporin A_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Dihydroartemisinin_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the BI-3406_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Malotilate_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Fostamatinib (disodium hexahydrate)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Busulfan_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Neratinib_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Sunitinib_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pitavastatin (Calcium)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Bestatin (hydrochloride)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Valdecoxib_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Methylprednisolone succinate_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Carbidopa (monohydrate)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Eplerenone_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the S-Adenosyl-L-methionine (disulfate tosylate)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Belinostat_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Phenylephrine (hydrochloride)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Cinacalcet_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the SBI-0640756_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Gemfibrozil_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Vandetanib_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the 5-Fluorouracil_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Thymol_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Tucidinostat_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Dimethyl fumarate_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Captopril_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the MK-8353_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Aspirin_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Menadione_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Oxaprozin_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Lenalidomide (hemihydrate)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Artemether_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Folic acid_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Lumateperone (tosylate)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Indacaterol (maleate)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Acetazolamide_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Asciminib_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Benproperine (phosphate)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Verapamil_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Tofacitinib_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Canagliflozin (hemihydrate)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the L-Thyroxine (sodium salt pentahydrate)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Canagliflozin_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Encorafenib_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Trametinib_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Capmatinib_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the γ-Oryzanol_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Methylthiouracil_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Larotrectinib sulfate_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Chlorhexidine (diacetate)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Monocrotaline_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Rosiglitazone_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Uridine_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Docetaxel (Trihydrate)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Rutin (trihydrate)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Apalutamide_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Hesperidin_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Aprepitant_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Terfenadine_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Hexylresorcinol_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the 5-Azacytidine_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Clopidogrel_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Clobetasol propionate_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Fluvoxamine_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Doxycycline (monohydrate)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Auranofin_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Panobinostat_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Entecavir (monohydrate)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Ouabain (Octahydrate)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Posaconazole_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Cytarabine_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Ranolazine_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Fumaric acid_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Mozavaptan_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Penfluridol_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Estrone sulfate (potassium)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Glasdegib_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Imiquimod (maleate)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Ivermectin_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Methyl aminolevulinate (hydrochloride)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Bosentan (hydrate)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Simotinib_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Sivelestat (sodium tetrahydrate)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Glycyrrhizic acid_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Topotecan (hydrochloride)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Larotrectinib_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the TAK-901_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Methotrexate_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Cobimetinib_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Dapagliflozin ((2S)-1,2-propanediol, hydrate)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Paclitaxel_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pyridoxine (hydrochloride)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Doxorubicin (hydrochloride)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Rucaparib (phosphate)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Balsalazide (sodium hydrate)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Sonidegib_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Irinotecan (hydrochloride)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Benztropine (mesylate)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Afatinib_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the palbociclib_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the c-Kit-IN-1_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Adagrasib_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Omeprazole_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Tirabrutinib (hydrochloride)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Cabozantinib (S-malate)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Cytarabine (hydrochloride)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Bimiralisib_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pralsetinib_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Ponatinib_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Lactate (calcium)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Binimetinib_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the HI-TOPK-032_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the RMC-6236_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Elimusertib hydrochloride_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Filgotinib_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Trametinib (DMSO_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Alpelisib_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the LJI308_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Lapatinib ditosylate_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pemigatinib_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Sulfatinib_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Finasteride_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Acetohexamide_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the XRK3F2_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Sulfisoxazole_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Amsacrine_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the APTO-253_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Plicamycin_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Zileuton_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Ipatasertib_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the GSK1059615_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Tolcapone_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Saquinavir_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Vilanterol_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Lipoic acid_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Quinestrol_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Demeclocycline_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pentoxifylline_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Trifluridine_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Goserelin (acetate)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Loperamide (hydrochloride)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Vinblastine (sulfate)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Homoharringtonine_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Sildenafil_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Salicylic acid_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Berberine (chloride hydrate)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Tomivosertib_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the OTS514_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Niclosamide (olamine)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Sinomenine_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the 8-Hydroxyquinoline_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the MK-3903_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Gallic acid (hydrate)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Everolimus_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Irinotecan_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Lidocaine (hydrochloride)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the ML264_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Capivasertib_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pimitespib_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the 9-ING-41_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Aliskiren_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Clotrimazole_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Cloxacillin (sodium)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Volasertib_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Rifaximin_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Trimetrexate_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Bimatoprost_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Tucatinib_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pemetrexed_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Tofacitinib (citrate)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Resveratrol_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Nevirapine_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Infigratinib_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Nimesulide_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Triclosan_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Vitamin K4_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Quinidine (15% dihydroquinidine)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Fenofibrate_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Naproxen_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Perindopril (erbumine)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Tirabrutinib_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Harringtonine_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pioglitazone_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the venetoclax_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Palmatine (chloride)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Silodosin_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Idarubicin (hydrochloride)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Thymopentin_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the LY-2584702 (tosylate salt)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Torkinib_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Celecoxib_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Macitentan_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Hydroxyurea_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Bestatin_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Rimonabant (Hydrochloride)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Mitoxantrone (dihydrochloride)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Belumosudil_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Ligustrazine_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the BI-78D3_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Bicalutamide_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the EX229_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pasireotide (acetate)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Imiquimod (hydrochloride)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Fluvoxamine (maleate)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Dinaciclib_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Bentamapimod_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Darinaparsin_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Crizotinib (hydrochloride)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Azithromycin (hydrate)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Erdafitinib _NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the BAY1125976_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Daidzin_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Ataluren_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Nafamostat (mesylate)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Edoxaban (tosylate monohydrate)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pravastatin (sodium)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Ralimetinib dimesylate_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Flumatinib (mesylate)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Almonertinib (hydrochloride)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Ixazomib citrate_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Futibatinib_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Clofarabine_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the LY2090314_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Erythromycin_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Tazarotene_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Vemurafenib_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Altretamine_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Tadalafil_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Ornidazole_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Tolmetin_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pexidartinib (hydrochloride)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the olaparib_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Epirubicin (hydrochloride)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Procainamide (hydrochloride)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Allopurinol_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Betamethasone dipropionate_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Erlotinib_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN016_MCF10A.WT.HP_24H:H23 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN015_MCF10A_48H:H23 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN015_HEPG2_48H:H23 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN014_HEPG2_24H:H23 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN014_HEPG2_3H:H23 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN015_MCF10A.WT.HP_24H:H23 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN015_MCF10A.TP53.M_24H:H23 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN016_MCF10A.TP53.M_24H:H23 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN013_HEPG2_24H:H23 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN008_HEPG2_24H:H23 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN011_HEPG2_24H:H23 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN012_HEPG2_24H:H23 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN009_HEPG2_24H:H23 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.